Warning: The NCBI web site requires JavaScript to function. more...
Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer.
Sassen A, Diermeier-Daucher S, Sieben M, Ortmann O, Hofstaedter F, Schwarz S, Brockhoff G.
Breast Cancer Res. 2009;11(4):R50. Epub 2009 Jul 22.
Related citations
Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients.
Sassen A, Rochon J, Wild P, Hartmann A, Hofstaedter F, Schwarz S, Brockhoff G.
Breast Cancer Res. 2008;10(1):R2. Epub 2008 Jan 8.
Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.
Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE.
Breast Cancer Res. 2009;11(1):R11. Epub 2009 Feb 24.
The upgraded role of HER3 and HER4 receptors in breast cancer.
Koutras AK, Fountzilas G, Kalogeras KT, Starakis I, Iconomou G, Kalofonos HP.
Crit Rev Oncol Hematol. 2010 May;74(2):73-8. Epub 2009 May 30. Review.
Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S, Horváth G, Knuechel-Clarke R, Hofstaedter F, Szöllosi J, Brockhoff G.
Exp Cell Res. 2005 Apr 1;304(2):604-19. Epub 2005 Jan 21.
HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer.
Gijsen M, King P, Perera T, Parker PJ, Harris AL, Larijani B, Kong A.
PLoS Biol. 2010 Dec 21;8(12):e1000563.
Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
Razis E, Bobos M, Kotoula V, Eleftheraki AG, Kalofonos HP, Pavlakis K, Papakostas P, Aravantinos G, Rigakos G, Efstratiou I, Petraki K, Bafaloukos D, Kostopoulos I, Pectasides D, Kalogeras KT, Skarlos D, Fountzilas G.
Breast Cancer Res Treat. 2011 Jul;128(2):447-56. Epub 2011 May 19.
Update on HER-kinase-directed therapy in prostate cancer.
Gross ME, Jo S, Agus DB.
Clin Adv Hematol Oncol. 2004 Jan;2(1):53-6, 64. Review.
Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin).
Fuchs IB, Landt S, Bueler H, Kuehl U, Coupland S, Kleine-Tebbe A, Lichtenegger W, Schaller G.
Breast Cancer Res Treat. 2003 Nov;82(1):23-8.
EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.
Gori S, Sidoni A, Colozza M, Ferri I, Mameli MG, Fenocchio D, Stocchi L, Foglietta J, Ludovini V, Minenza E, De Angelis V, Crinò L.
Ann Oncol. 2009 Apr;20(4):648-54. Epub 2009 Feb 2.
MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells.
Fessler SP, Wotkowicz MT, Mahanta SK, Bamdad C.
Breast Cancer Res Treat. 2009 Nov;118(1):113-24. Epub 2009 May 5.
PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.
Wang L, Zhang Q, Zhang J, Sun S, Guo H, Jia Z, Wang B, Shao Z, Wang Z, Hu X.
BMC Cancer. 2011 Jun 15;11:11:248. doi: 10.1186/1471-2407-11-248.
Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials.
Baselga J.
Oncology. 2001;61 Suppl 2:14-21. Review.
Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
Chan CT, Metz MZ, Kane SE.
Breast Cancer Res Treat. 2005 May;91(2):187-201.
[Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance].
Dieras V, Vincent-Salomon A, Degeorges A, Beuzeboc P, Mignot L, de Cremoux P.
Bull Cancer. 2007 Mar;94(3):259-66. Review. French.
HER-2/neu expression in primary and metastatic breast cancer.
Lower EE, Glass E, Blau R, Harman S.
Breast Cancer Res Treat. 2009 Jan;113(2):301-6. Epub 2008 Feb 14.
Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.
Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM.
J Pathol. 2003 Jul;200(3):290-7.
Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A, Colomer R, Brunet J, Menendez JA.
Int J Oncol. 2007 Oct;31(4):769-76.
HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
Press MF, Finn RS, Cameron D, Di Leo A, Geyer CE, Villalobos IE, Santiago A, Guzman R, Gasparyan A, Ma Y, Danenberg K, Martin AM, Williams L, Oliva C, Stein S, Gagnon R, Arbushites M, Koehler MT.
Clin Cancer Res. 2008 Dec 1;14(23):7861-70.
Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability.
Kang SH, Kang KW, Kim KH, Kwon B, Kim SK, Lee HY, Kong SY, Lee ES, Jang SG, Yoo BC.
BMC Cancer. 2008 Oct 4;8:286.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on